openPR Logo
Press release

Severe Asthma FDA Approvals, Clinical Trials, Emerging Drugs, Pipeline Insights and Companies | DelveInsight

02-04-2025 11:46 PM CET | Health & Medicine

Press release from: ABNewswire

Severe Asthma FDA Approvals, Clinical Trials, Emerging Drugs,

DelveInsight's, "Severe Asthma Pipeline Insight" report provides comprehensive insights about 40+ companies and 50+ pipeline drugs in Severe Asthma pipeline landscape. It covers the Severe Asthma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Severe Asthma Treatment Landscape. Click here to read more @ Severe Asthma Pipeline Outlook [https://www.delveinsight.com/sample-request/severe-asthma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Severe Asthma Pipeline Report

* In January 2025:- AstraZeneca:- This is a multicentre, randomised, open-label, parallel-group, phase IIIb study to assess the potential for tezepelumab-treated patients to (1) reduce maintenance therapy without the loss of asthma control at Week 56, among those who demonstrated asthma control or low biomarkers at Week 24, and (2) be in asthma control and have characteristics of clinical remission at Week 24.
* In January 2025: Upstream Bio Inc.:- The purpose of this study is to evaluate the efficacy and safety of verekitug (UPB-101) in participants with severe asthma. The study will evaluate the incidence of asthma exacerbations, other pharmacodynamic (PD) parameters such as lung function and asthma control, and the safety and tolerability of verekitug (UPB-101) compared to placebo.
* In January 2025:- Incyte Corporation:- A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma. The study is being conducted to evaluate the effect of 3 dosing regimens of povorcitinib on pulmonary function.
* DelveInsight's Severe Asthma Pipeline analysis depicts a robust space with 40+ active players working to develop 50+ pipeline treatment therapies.
* The leading Severe Asthma Companies such as Kinaset Therapeutics, Bio-Thera Solutions, CSPC ZhongQi Pharmaceutical Technology, AB Science, GlaxoSmithKline, Oneness Biotech, Biosion, Lanier Biotherapeutics, Kymera Therapeutics, Suzhou Connect Biopharmaceuticals, Upstream Bio, Teva Branded Pharmaceutical Industries, and others.
* Promising Severe Asthma Therapies such as Verekitug (UPB-101), FB704A, TQC2731, Benralizumab, povorcitinib, CM326 , and others.

Stay informed about the cutting-edge advancements in Severe Asthma treatments. Download for updates and be a part of the revolution in Respiratory Diseases care @ Severe Asthma Clinical Trials Assessment [https://www.delveinsight.com/sample-request/severe-asthma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Severe Asthma Emerging Drugs

* GSK3511294: GlaxoSmithKline

GSK 3511294, also known as depemokimab, is a long acting, interleukin-5 (IL-5) receptor antagonistic monoclonal antibody, being developed by GlaxoSmithKline, for the treatment of asthma. GSK3511294 is a humanized anti-interleukin (IL)-5 monoclonal antibody (mAb) engineered for extended half-life and improved IL-5 affinity versus other anti-IL-5 mAbs. Currently the drug is in Phase III stage of Clinical trial evaluation for the treatment of severe asthma.

* BSI-045B: Biosion

BSI-045B is a high-affinity, humanized monoclonal antibody, targeting thymic stromal lymphopoietin (TSLP), a cytokine that is implicated in the pathogenesis of atopic dermatitis, asthma and other eosinophilic and Th2 immune-related diseases. Biosion's collaboration partner - CTTQ, a China-based pharmaceutical company with rights to BSI-045B (TQC2731) for China development and commercialization, is currently conducting a Phase II clinical trial of BSI-045B in China for the treatment of severe uncontrolled asthma.

* Mepolizumab: Bio-Thera Solutions

Mepolizumab is an interleukin-5 (IL-5) antagonist monoclonal antibody administered subcutaneously via syringe or autoinjector. It is currently indicated for several conditions: as an add-on maintenance treatment for adult and pediatric patients aged six years and older with severe asthma characterized by an eosinophilic phenotype; as an add-on maintenance treatment for adult patients aged 18 years and older with chronic rhinosinusitis with nasal polyps; for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis; and for the treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome of at least six months' duration without an identifiable non-hematologic secondary cause. Currently the drug is in Phase I stage of its clinical trial for the treatment of severe asthma.

Explore groundbreaking therapies and clinical trials in the Severe Asthma Pipeline. Access DelveInsight's detailed report now! @ Severe Asthma Treatment Drugs [https://www.delveinsight.com/sample-request/severe-asthma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Severe Asthma Companies

Kinaset Therapeutics, Bio-Thera Solutions, CSPC ZhongQi Pharmaceutical Technology, AB Science, GlaxoSmithKline, Oneness Biotech, Biosion, Lanier Biotherapeutics, Kymera Therapeutics, Suzhou Connect Biopharmaceuticals, Upstream Bio, Teva Branded Pharmaceutical Industries, and others.

Severe Asthma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical

Severe Asthma Products have been categorized under various Molecule types such as

* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy

Unveil the future of Severe Asthma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Severe Asthma Market Drivers and Barriers [https://www.delveinsight.com/sample-request/severe-asthma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Severe Asthma Pipeline Report

* Coverage- Global
* Severe Asthma Companies- Kinaset Therapeutics, Bio-Thera Solutions, CSPC ZhongQi Pharmaceutical Technology, AB Science, GlaxoSmithKline, Oneness Biotech, Biosion, Lanier Biotherapeutics, Kymera Therapeutics, Suzhou Connect Biopharmaceuticals, Upstream Bio, Teva Branded Pharmaceutical Industries, and others.
* Severe Asthma Therapies- Verekitug (UPB-101), FB704A, TQC2731, Benralizumab, povorcitinib, CM326, and others.
* Severe Asthma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Severe Asthma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Severe Asthma Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Severe Asthma Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/severe-asthma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* Severe Asthma: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Severe Asthma- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* GSK3511294: GlaxoSmithKline
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* BSI-045B: Biosion
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Mepolizumab: Bio-Thera Solutions
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Severe Asthma Key Companies
* Severe Asthma Key Products
* Severe Asthma- Unmet Needs
* Severe Asthma- Market Drivers and Barriers
* Severe Asthma- Future Perspectives and Conclusion
* Severe Asthma Analyst Views
* Severe Asthma Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=severe-asthma-fda-approvals-clinical-trials-emerging-drugs-pipeline-insights-and-companies-delveinsight]
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/dyspepsia-market



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Severe Asthma FDA Approvals, Clinical Trials, Emerging Drugs, Pipeline Insights and Companies | DelveInsight here

News-ID: 3849958 • Views:

More Releases from ABNewswire

Thrombectomy Devices Market is poised for consistent growth through 2032, propelled by technological advancements and the rising number of surgical procedures, according to DelveInsight. Major players
Thrombectomy Devices Market is poised for consistent growth through 2032, propel …
The thrombectomy devices market was valued at USD 1,656.88 million in 2024, growing at a CAGR of 6.83% during the forecast period from 2025 to 2032 to reach USD 2,806.85 million by 2032. Valued at USD 1,656.88 million in 2024, the market is expected to expand at a CAGR of 6.83% from 2025 to 2032, reaching approximately USD 2,806.85 million by the end of the period. This upward trajectory is driven
VinaSources Partners With Viettel Post at VIS 2025 to Boost Global Reach for Vietnamese Goods
VinaSources Partners With Viettel Post at VIS 2025 to Boost Global Reach for Vie …
HANOI - 22 October, 2025 - VinaSources, a sourcing platform connecting global buyers with verified Vietnamese manufacturers, has officially announced its strategic partnership with Viettel Post, Vietnam's leading logistics provider. The agreement was formalized during the Vietnam International Sourcing EXPO 2025 (VIS 2025), held from 4 to 6 September in Ho Chi Minh City. The collaboration brings together VinaSources' verified supplier network and Viettel Post's cross-border logistics services, offering international buyers
JCFLOW Launches Trendy Beads Box Sets and 15mm Silicone Beads Collections to Empower Global DIY Makers and Small Businesses
JCFLOW Launches Trendy Beads Box Sets and 15mm Silicone Beads Collections to Emp …
JCFLOW [https://jcflowbeads.com/], a registered silicone bead factory store based in Las Vegas with production facilities in China, continues to expand its creative horizons by introducing two signature product collections: the Beads Box Set Series and the 15mm Silicone Beads Collection. Designed for crafters, jewelry designers, and small business owners, these collections highlight JCFLOW's dedication to providing factory-direct, customizable, and affordable silicone bead solutions for every creative need. The Beads Box Set
New Jersey DUI Attorney Rachel Kugel Highlights Blood Alcohol Content Laws and EtG Testing
New Jersey DUI Attorney Rachel Kugel Highlights Blood Alcohol Content Laws and E …
Newark, NJ - Rachel Kugel, a distinguished New Jersey DUI attorney and founder of The Kugel Law Firm (https://thekugellawfirm.com/new-jersey-etg-calculator/), is bringing attention to the role of Blood Alcohol Content (BAC) thresholds, EtG testing, and the use of BAC calculators in drunk driving cases. With New Jersey's DUI laws carrying serious penalties, including fines, license suspensions, and possible jail time, understanding how alcohol levels are measured is essential for drivers across

All 5 Releases


More Releases for Severe

Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne Clinical Trials, Compan …
DelveInsight's "Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne, historical and forecasted epidemiology as well as the Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. DelveInsight's analysis highlights that several key companies are actively
Severe Combined Immunodeficiency (SCID) Market: A Comprehensive Overview
Severe Combined Immunodeficiency (SCID) is a rare but life-threatening genetic disorder that affects the immune system, leaving individuals vulnerable to infections. It is often referred to as "bubble boy disease," due to its dramatic impact on the immune system, which fails to protect the body from pathogens. SCID can be caused by various mutations in different genes, and it leads to a complete or near-complete absence of functional T-cells and
Severe Breathing Care Ventilator Market Size 2024 to 2031.
Market Overview and Report Coverage The Severe Breathing Care Ventilator Market refers to the market for medical devices that help patients with severe breathing difficulties by providing assistance with their respiration. These ventilators are crucial in treating patients with conditions such as respiratory failure, chronic obstructive pulmonary disease (COPD), and acute respiratory distress syndrome (ARDS). The future outlook for the Severe Breathing Care Ventilator Market is very promising, with a
Severe Asthma Treatment Market - Revitalizing Quality of Life: Severe Asthma Tre …
Newark, New Castle, USA: The "Severe Asthma Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors. Severe Asthma Treatment Market: https://www.growthplusreports.com/report/severe-asthma-treatment-market/8939 This latest report researches the industry structure,
Severe Hypertriglyceridemia Market - Breaking Barriers in Managing Cholesterol L …
Newark, New Castle, USA: The "Severe Hypertriglyceridemia Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors. Severe Hypertriglyceridemia Market: https://www.growthplusreports.com/report/severe-hypertriglyceridemia-market/8763 This latest report researches the industry structure, sales, revenue,
Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H1 2017 to its growing collection of premium market research reports. Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H1 2017, provides an overview of the Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) pipeline landscape. Severe acute respiratory syndrome (SARS) is a serious, potentially